ATE552273T1 - Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können - Google Patents

Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können

Info

Publication number: ATE552273T1
Authority: AT; Austria
Prior art keywords: module; survival; cells; compounds; immunoglobulin
Prior art date: 2001-08-17

Application number

AT02794729T

Other languages

English (en)

Inventor

Vladislav Kiselyov

Galina Skladchikova

Vladimir Berezin

Elisabeth Bock

Original Assignee

Enkam Pharmaceuticals As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-17

Filing date

2002-08-19

Publication date

2012-04-15

2002-08-19 Application filed by Enkam Pharmaceuticals As filed Critical Enkam Pharmaceuticals As

2012-04-15 Application granted granted Critical

2012-04-15 Publication of ATE552273T1 publication Critical patent/ATE552273T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 5
230000004069 differentiation Effects 0.000 title abstract 2
230000035755 proliferation Effects 0.000 title abstract 2
230000008929 regeneration Effects 0.000 title abstract 2
238000011069 regeneration method Methods 0.000 title abstract 2
230000004083 survival effect Effects 0.000 title 1
108060003951 Immunoglobulin Proteins 0.000 abstract 3
102000018358 immunoglobulin Human genes 0.000 abstract 3
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 abstract 2
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 abstract 2
102000018233 Fibroblast Growth Factor Human genes 0.000 abstract 2
108050007372 Fibroblast Growth Factor Proteins 0.000 abstract 2
102000016359 Fibronectins Human genes 0.000 abstract 2
108010067306 Fibronectins Proteins 0.000 abstract 2
108010069196 Neural Cell Adhesion Molecules Proteins 0.000 abstract 2
102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 abstract 2
229960001456 adenosine triphosphate Drugs 0.000 abstract 2
229940126864 fibroblast growth factor Drugs 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
210000004027 cell Anatomy 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000007996 neuronal plasticity Effects 0.000 abstract 1
230000006576 neuronal survival Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Diabetes (AREA)
Psychology (AREA)
Cell Biology (AREA)
Reproductive Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Toxicology (AREA)
Zoology (AREA)
Dermatology (AREA)
Obesity (AREA)

AT02794729T 2001-08-17 2002-08-19 Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können ATE552273T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200101228		2001-08-17
DKPA200200667		2002-05-02
PCT/DK2002/000541 WO2003016351A2 (en)	2001-08-17	2002-08-19	N - cam related compounds modulating cell groth

Publications (1)

Publication Number	Publication Date
ATE552273T1 true ATE552273T1 (de)	2012-04-15

Family

ID=26069061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02794729T ATE552273T1 (de)	2001-08-17	2002-08-19	Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können

Country Status (6)

Country	Link
US (2)	US20040242479A1 (de)
EP (1)	EP1434798B1 (de)
JP (1)	JP4402455B2 (de)
AT (1)	ATE552273T1 (de)
CA (1)	CA2457164A1 (de)
WO (1)	WO2003016351A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE552273T1 (de)	2001-08-17	2012-04-15	Enkam Pharmaceuticals As	Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können
JP2007524566A (ja)	2002-12-20	2007-08-30	エンカムファーマシューティカルズアクティーゼルスカブ	レセプターとリガンドの間の相互作用の調節の方法
US20090105149A1 (en) *	2003-08-07	2009-04-23	Enkam Pharmaceuticals A/S	Compounds comprising lpa
EP1678200B1 (de) *	2003-09-30	2012-05-02	Enkam Pharmaceuticals A/S	Verfahren zur modulierung des überlebens von zellen, der differenzierung und/oder der synaptischen plastizität
ATE545655T1 (de) *	2004-06-18	2012-03-15	Enkam Pharmaceuticals As	Fgfr-bindende peptide
JP2009511613A (ja) *	2005-10-17	2009-03-19	エンカムファーマシューティカルズアクティーゼルスカブ	神経細胞接着分子ｌ１のペプチド断片を含む新規ｆｇｆ受容体結合化合物
AU2006315562C1 (en) *	2005-11-12	2013-10-03	The Board Of Trustees Of The Leland Stanford Junior University	Methods for treating depression using NCAM peptide mimetics
WO2007110079A2 (en) *	2006-03-29	2007-10-04	Enkam Pharmaceuticals A/S	Targeted delivery of fgfr ligands into the brain
WO2009068042A2 (en) *	2007-11-28	2009-06-04	Enkam Pharmaceuticals A/S	Novel peptides derived from ncam (fgls)
WO2010065995A1 (en) *	2008-12-08	2010-06-17	Vegenics Limited	Isolated vegf-c and vegf-d peptides and uses thereof
US8637465B2 (en) *	2009-05-27	2014-01-28	Kobenhavns Universitet	Fibroblast growth factor receptor-derived peptides binding to NCAM
WO2013184824A1 (en)	2012-06-05	2013-12-12	The Board Of Trustees Of The Leland Stanford Junior University	Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics
US11220669B2 (en) *	2015-06-05	2022-01-11	Amolifescience Co., Ltd.	Defined three dimensional microenvironment for cell culture

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4599311A (en)	1982-08-13	1986-07-08	Kawasaki Glenn H	Glycolytic promotersfor regulated protein expression: protease inhibitor
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US5010175A (en)	1988-05-02	1991-04-23	The Regents Of The University Of California	General method for producing and selecting peptides with specific properties
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5629291A (en) *	1992-01-31	1997-05-13	La Jolla Cancer Research Foundation	Methods of modulating fibronectin extracellular matrix assembly
US5840689A (en) *	1993-10-29	1998-11-24	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Method for stimulating the regrowth of neurons
US5693488A (en) *	1994-05-12	1997-12-02	The Rockefeller University	Transmembrane tyrosine phosphatase, nucleic acids encoding the same, and methods of use thereof
US6576607B1 (en) *	1995-04-19	2003-06-10	Acorda Therapeutics	Methods using CNS neurite outgrowth modulators
US6313265B1 (en) *	1995-07-24	2001-11-06	The Scripps Research Institute	Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use
DE69912827T2 (de)	1998-09-29	2004-10-21	Loke Diagnostics Aps Aarhus	"ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen
US7504490B1 (en) *	1998-10-16	2009-03-17	Oscient Pharmaceuticals Corporation	Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
MEP42108A (en)	1998-10-23	2011-02-10	Kiren Amgen Inc	Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US7167819B1 (en) *	1999-05-26	2007-01-23	Chiron Corporation	Method of determining the three-dimensional shape of a macromolecule
US6749850B1 (en)	1999-08-18	2004-06-15	The General Hospital Corporation	Methods, compositions and kits for promoting recovery from damage to the central nervous system
AU7078200A (en)	1999-08-27	2001-03-26	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
GB0014870D0 (en) *	2000-06-16	2000-08-09	King S College London	Peptides
ATE552273T1 (de)	2001-08-17	2012-04-15	Enkam Pharmaceuticals As	Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können
JP2007524566A (ja)	2002-12-20	2007-08-30	エンカムファーマシューティカルズアクティーゼルスカブ	レセプターとリガンドの間の相互作用の調節の方法
US20090105149A1 (en)	2003-08-07	2009-04-23	Enkam Pharmaceuticals A/S	Compounds comprising lpa

2002
- 2002-08-19 AT AT02794729T patent/ATE552273T1/de active
- 2002-08-19 CA CA002457164A patent/CA2457164A1/en not_active Abandoned
- 2002-08-19 EP EP02794729A patent/EP1434798B1/de not_active Expired - Lifetime
- 2002-08-19 WO PCT/DK2002/000541 patent/WO2003016351A2/en not_active Ceased
- 2002-08-19 JP JP2003521273A patent/JP4402455B2/ja not_active Expired - Fee Related
- 2002-08-19 US US10/486,731 patent/US20040242479A1/en not_active Abandoned
2009
- 2009-05-04 US US12/435,043 patent/US8071549B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2003016351A2 (en)	2003-02-27
US8071549B2 (en)	2011-12-06
US20040242479A1 (en)	2004-12-02
US20090305951A1 (en)	2009-12-10
JP4402455B2 (ja)	2010-01-20
WO2003016351A3 (en)	2004-03-25
EP1434798A2 (de)	2004-07-07
EP1434798B1 (de)	2012-04-04
WO2003016351B1 (en)	2004-05-06
JP2005510463A (ja)	2005-04-21
CA2457164A1 (en)	2003-02-27

Publication	Publication Date	Title
ATE552273T1 (de)	2012-04-15	Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können
BR0016150A (pt)	2002-08-13	Compostos, composições e métodos para estìmulo de crescimento e alongamento neuronal
DE60224291D1 (de)	2008-02-07	System zur antikörperexpression und- synthese
WO1996006108A3 (en)	1996-03-21	Cyclic cs-1 peptidomimetics, compositions and methods of using the same
ATE259828T1 (de)	2004-03-15	Prosaposin und cytokinabhängige peptide als therapeutisch wirksame mittel
DE69435038D1 (de)	2007-12-06	Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
ATE291011T1 (de)	2005-04-15	Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
IL195337A0 (en)	2009-08-03	Cyr61 compositions and methods
EA199800301A1 (ru)	1998-10-29	Усеченный нейротрофический фактор глиальной клеточной линии
PT1042291E (pt)	2005-11-30	Piridilalcano, alceno e alcino carboxamidas substituidas com arilo, uteis como agentes citostaticos e imunossupressores
AU2003209636A1 (en)	2003-09-09	Novel chemokine binding peptides capable of modulating the biological activity of chemokines
EP1572937A4 (de)	2007-08-08	Mit motiven transplantierte hybrid-polypeptide und verwendungen davon
DE69426033D1 (de)	2000-11-02	Für die alpha-1e untereinheit des menschlichen kalziumkanals kodierende dna
DE69726884D1 (de)	2004-01-29	Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
CY1106070T1 (el)	2011-06-08	Πολυμορφισμοι στο γονιδιο c μεταφορας οργανικου ανιοντος ανθρωπου (oatp-c) - (organic anion transporter c gene)
DE60238038D1 (de)	2010-12-02	Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen
FI964781A0 (fi)	1996-11-29	Uusia elastaasi-inhibiittoreita
ATE314390T1 (de)	2006-01-15	Genetisch manipulierte zellen die knochenmorphogeneseproteinen exprimieren
ATE263239T1 (de)	2004-04-15	Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
BR9811853A (pt)	2000-08-08	Processos para aumentar o rendimento em plantas
DE69328060D1 (de)	2000-04-20	Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
ATE431361T1 (de)	2009-05-15	Verwendung vom transportergen oatp-c zur screening von testsubstanzen
BR0307470A (pt)	2006-12-19	fração de plasma de um animal hibernante e métodos de purificar uma molécula tendo atividade anti-infarto, de reduzir um infarto em um indivìduo de produzir e de identificar uma molécula anti-infarto e de identificar um inibidor da interação entre a bradicinina e o tipo 2 do receptor de angiotensina ii
ATE545655T1 (de)	2012-03-15	Fgfr-bindende peptide
WO2009068042A3 (en)	2009-07-30	Novel peptides derived from ncam (fgls)